Exor N.V. has announced a planned increase in its direct ownership of bioMérieux, raising its stake to 8.53% from the current 3.87%, the companies said in a joint statement. The move will be carried out through a transfer of bioMérieux shares to Exor that is effected by reducing the share capital of Institut Mérieux.
The mechanism described involves Exor exchanging part of its shareholding in Institut Mérieux for ordinary shares in bioMérieux. Following the operation, Institut Mérieux will remain the dominant shareholder in bioMérieux, retaining 55.24% of the company's share capital and 68.67% of its voting rights once the transaction is completed.
Company documents indicate the transaction is expected to be completed in December 2026. That timing is conditional: the closing is subject to the creditor objection period and requires approval from the shareholders of Institut Mérieux. Those procedural steps must be resolved before the transfer becomes final.
Upon conclusion of the exchange, Exor's direct interest in bioMérieux will stand at 8.53% of the share capital and represent 5.35% of the voting rights. At the same time, Exor's stake in Institut Mérieux will be reduced to 5.02% of share capital and to 2.58% of voting rights as a result of the share capital decrease.
Exor first acquired a position in Institut Mérieux in 2022 and subsequently began holding shares directly in bioMérieux in 2025. The planned transaction represents a reallocation of Exor's holdings between the two entities rather than an acquisition of newly issued bioMérieux shares.
bioMérieux's Board of Directors has indicated it will propose Benoît Ribadeau-Dumas as Exor's representative at the next Annual General Meeting. Ribadeau-Dumas currently serves on the board of Institut Mérieux and acts as a non-voting observer on bioMérieux's Board.
Both Exor and the Mérieux family have stated they do not intend to act in concert with respect to bioMérieux. The governance framework of Institut Mérieux is expected to remain unchanged after the transaction.
Contextual summary
The arrangement transfers a larger direct economic interest in bioMérieux to Exor while leaving Institut Mérieux as the majority shareholder and preserving its governance structure. The timetable reaches into late 2026 and depends on standard closing conditions and approvals.